SG10201506881PA - Biomarkers for cancers responsive to modulators of hec1 activity - Google Patents

Biomarkers for cancers responsive to modulators of hec1 activity

Info

Publication number
SG10201506881PA
SG10201506881PA SG10201506881PA SG10201506881PA SG10201506881PA SG 10201506881P A SG10201506881P A SG 10201506881PA SG 10201506881P A SG10201506881P A SG 10201506881PA SG 10201506881P A SG10201506881P A SG 10201506881PA SG 10201506881P A SG10201506881P A SG 10201506881PA
Authority
SG
Singapore
Prior art keywords
biomarkers
modulators
cancers responsive
hec1
activity
Prior art date
Application number
SG10201506881PA
Inventor
Yu-Ling Huang
Johnson Lau
Original Assignee
Taivex Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taivex Therapeutics Corp filed Critical Taivex Therapeutics Corp
Publication of SG10201506881PA publication Critical patent/SG10201506881PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
SG10201506881PA 2011-11-21 2012-11-19 Biomarkers for cancers responsive to modulators of hec1 activity SG10201506881PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161562177P 2011-11-21 2011-11-21

Publications (1)

Publication Number Publication Date
SG10201506881PA true SG10201506881PA (en) 2015-10-29

Family

ID=48470233

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201402143YA SG11201402143YA (en) 2011-11-21 2012-11-19 Biomarkers for cancers responsive to modulators of hec1 activity
SG10201506881PA SG10201506881PA (en) 2011-11-21 2012-11-19 Biomarkers for cancers responsive to modulators of hec1 activity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201402143YA SG11201402143YA (en) 2011-11-21 2012-11-19 Biomarkers for cancers responsive to modulators of hec1 activity

Country Status (10)

Country Link
US (1) US9976183B2 (en)
EP (1) EP2783217B1 (en)
JP (1) JP6099662B2 (en)
CN (1) CN104395752B (en)
ES (1) ES2736999T3 (en)
HK (1) HK1202922A1 (en)
MX (1) MX2014006088A (en)
SG (2) SG11201402143YA (en)
TW (3) TWI681054B (en)
WO (1) WO2013078145A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103038231B (en) 2010-03-17 2016-04-20 泰纬生命科技股份有限公司 HEC1 active regulator and method thereof
US11071736B2 (en) * 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
TWI640519B (en) * 2011-11-29 2018-11-11 泰緯生命科技股份有限公司 Modulators of hec1 activity and methods therefor
GB201820975D0 (en) * 2018-12-21 2019-02-06 Fund Calouste Gulbenkian Methods of cancer treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1519736A2 (en) * 2002-06-12 2005-04-06 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
US8252520B2 (en) 2002-10-11 2012-08-28 Taivex Therapeutics Corporation Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases
RU2006111093A (en) 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) MODULATORS OF ATR-BINDING CASSETTE TRANSPORTERS
EP2395108A1 (en) * 2004-12-08 2011-12-14 Aventis Pharmaceuticals Inc. Method for measuring resistance or sensitivity to docetaxel
WO2007004038A1 (en) 2005-07-05 2007-01-11 Pfizer Products Inc. Aminothiazole derivatives as agonists of the thrombopoietin receptor
KR100861278B1 (en) * 2008-02-19 2008-10-01 고려대학교 산학협력단 Ribonucleic acid-based pharmaceutical composition for treating cancer
CN102088973A (en) 2008-05-15 2011-06-08 杜克大学 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
EP2309273B1 (en) * 2009-09-16 2016-05-18 ZEILLINGER, Robert Novel tumor marker determination
CN103038231B (en) * 2010-03-17 2016-04-20 泰纬生命科技股份有限公司 HEC1 active regulator and method thereof

Also Published As

Publication number Publication date
HK1202922A1 (en) 2015-10-09
TW201705987A (en) 2017-02-16
TW201706416A (en) 2017-02-16
JP2015500008A (en) 2015-01-05
EP2783217A1 (en) 2014-10-01
JP6099662B2 (en) 2017-03-22
US9976183B2 (en) 2018-05-22
EP2783217B1 (en) 2019-04-24
MX2014006088A (en) 2015-04-08
SG11201402143YA (en) 2014-06-27
TW201331371A (en) 2013-08-01
ES2736999T3 (en) 2020-01-09
TWI641386B (en) 2018-11-21
WO2013078145A1 (en) 2013-05-30
EP2783217A4 (en) 2015-05-27
CN104395752B (en) 2017-09-15
CN104395752A (en) 2015-03-04
TWI681054B (en) 2020-01-01
US20130171634A1 (en) 2013-07-04
TWI681055B (en) 2020-01-01

Similar Documents

Publication Publication Date Title
HK1216310A1 (en) Heterocyclic modulators of lipid synthesis
ZA201502433B (en) Methods of host cell modification
HK1208445A1 (en) Heterocyclic modulators of lipid synthesis
IL228001B (en) Antibodies to cd70
EP2771455A4 (en) Cell line for production of adeno-associated virus
EP2736919A4 (en) NOVEL 17ß-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
HK1204604A1 (en) Stereoselective total synthesis of noribogaine
EP2690442A4 (en) Marker for determination of sensitivity to anticancer agent
HK1192323A1 (en) Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles glu-
GB201118302D0 (en) Improvements to tyres
EP2776586A4 (en) Biomarkers of response to proteasome inhibitors
HK1189056A1 (en) Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles bubr1
HK1203355A1 (en) Uses of 4-desferrithiocin analogs 4-
HK1202922A1 (en) Biomarkers for cancers responsive to modulators of hec1 activity hec1
EP2694705A4 (en) Microfrabication of tunnels
GB2510539B (en) Biomarkers of cancer
EP2932272A4 (en) Shon as a prognostic biomarker for cancer and as a predictor of response to endocrine therapy
EP2776043A4 (en) Biomarkers of response to proteasome inhibitors
EP2809685A4 (en) Electrochemical synthesis of chloro-chitosan
GB201201857D0 (en) Pseudonymisation/de-pseudonymisation of data
GB201118205D0 (en) Predictive biomarker for responsiveness to cancer agents